Predict your next investment

HEALTHCARE | Stealth Mode
amphoramedical.com

See what CB Insights has to offer

Stage

Series B | Dead

Total Raised

$48.28M

Last Raised

$35.5M

About Amphora Medical

Amphora Medical is a stealth healthcare company led by Tom Ressemann, former CEO of Entellus Medical.

Amphora Medical Headquarter Location

6901 East Fish Lake Road Suite 106

Osseo, Minnesota, 55369,

United States

763-220-3730

Latest Amphora Medical News

Amphora raises $36M to trial overactive bladder treatment

Aug 17, 2017

Jul 21, 2017 6:47am Amphora plans to start a pivotal trial once it completes two ongoing feasibility studies. Amphora Medical has raised $35.5 million to put its overactive bladder (OAB) treatment through a pivotal clinical trial. The series B round equips Amphora to take its minimally invasive, cystoscopic device into the last step of clinical development next year. Longitude Capital and Boston Scientific led the round with the support of fellow new investor HBM Healthcare Investments. F-Prime Capital Partners and Baird Capital, the VCs that led Amphora’s $12.8 million series A in 2013, also chipped in to the latest financing. Amphora attracted the investment on the strength of the potential for its device to improve the lives of people with OAB, a condition associated with the sudden, hard-to-control need to urinate. Estimates of the prevalence of OAB cluster around 16%. Today, people typically try to manage OAB with behavioral interventions before advancing to drugs that relax the bladder or Botox injections. Another option is to insert a pacemaker-like device to regulate nerve impulses to the bladder. Minneapolis, MN-based Amphora thinks its device can offer a better option to some patients. Like the Nuro system Medtronic gained in its 2014 acquisition of Advanced Uro-Solutions, Amphora’s device seeks to modify nerve activity. But whereas Nuro delivers electrical pulses, the Selective Bladder Denervation System developed by Amphora destroys tissue to dial down signals sent from the bladder. Amphora thinks it can act on the nerves responsible for OAB without affecting those needed for the normal functioning of the bladder. Amphora is currently testing the device in more than 100 patients in two trials taking place in the U.S., Canada and Belgium. Data from these studies will propel Amphora into a pivotal trial in the U.S. “Upon the completion of two ongoing feasibility studies, we expect to initiate the pivotal, randomized, sham-controlled, selective bladder denervation clinical trial in women who are refractory to medical therapy in 2018,” Amphora CEO Tom Ressemann said in a statement. Read more on overactive bladder , medical device venture capital , venture capital (VC) , clinical trial , devices , Boston Scientific , Medtronic , Fidelity Biosciences , Longitude Capital Popular Content

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Amphora Medical

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Amphora Medical is included in 1 Expert Collection, including Medical Devices.

M

Medical Devices

7,890 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

Amphora Medical Patents

Amphora Medical has filed 10 patents.

The 3 most popular patent topics include:

  • Gynaecology
  • Urology
  • Incontinence
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/4/2015

2/11/2020

Thalamus, Hypothalamus, Thalamic nuclei, Sensory systems, Urinary system

Grant

Application Date

2/4/2015

Grant Date

2/11/2020

Title

Related Topics

Thalamus, Hypothalamus, Thalamic nuclei, Sensory systems, Urinary system

Status

Grant

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.